Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597503 · ClinicalTrials.gov registry record · Phase 3
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT03597503 is a Phase 3 study that was terminated before completion, run by Supernus Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT03597503, a Phase 3 study, was terminated before completion, sponsored by Supernus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
Interventions
- DRUG Placebo
- DRUG SPN-810
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2020-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597503
The ClinicalTrials.gov registry entry for NCT03597503 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03597503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597503 about?
NCT03597503 is a clinical study titled "Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment". The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
What is the current status of trial NCT03597503?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2018-07-31. Estimated completion is 2020-01-22.
What interventions are being tested in trial NCT03597503?
The interventions under investigation include: Placebo (DRUG), SPN-810 (DRUG).
Who is sponsoring clinical trial NCT03597503?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.